The release and related presentation material in Finnish and in English will be available on the Group’s homepage at www.orion.fi/investors promptly after the publishing.
will publish its Financial Statement Release for 2017 on Wednesday, 7 February 2018 approximately at 12.00 noon Finnish time (EET). The release and related presentation material in Finnish and in English will be available on the Group’s homepage at www.orion.fi/investors promptly after the publishing.
News conference for analysts and media
A news conference for analysts and media will be held on Wednesday, 7 February 2018 at 13.30 EET at Orion’s head office, address Orionintie 1A, Espoo. President and CEO Timo Lappalainen will give a brief presentation in English on the financial review. Questions can be asked after the presentation also via teleconference. Participants should be prepared to present a photo ID.
Live webcast and conference call
A link to the live webcast will be available on Orion’s website at www.orion.fi/investors.
The conference call ID is 8162605 and the phone numbers to participate the conference are:
Finland: +358 (0)9 7479 0361
Sweden: +46 (0)8 5033 6574
UK: +44 (0)330 336 9105
USA: +1 323-794-2093
News conference recordings
A recording of the event in English and a recording of the presentation by the President and CEO in Finnish will be available on Orion’s website later the same day.
Silent period
The silent period preceding the publication is ongoing and continues until the disclosure.
Contact person:
Lilli Riikonen, Communications Manager, tel. +358 10 426 2319
Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo
Homepage: www.orion.fi/en
Orion is a globally operating Finnish pharmaceutical company - a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion’s pharmaceutical R&D are central nervous system (CNS) disorders, oncology and respiratory diseases for which Orion develops inhaled Easyhaler® pulmonary drugs. Orion’s net sales in 2016 amounted to EUR 1,074 million and the company had about 3,500 employees. Orion’s A and B shares are listed on Nasdaq Helsinki.
